Skip to content
Peptide research

Sermorelin

Also known as Geref · GRF 1-29
Category
Growth Hormone
Administration routes
Injectable
Regulatory status
Not FDA-approved

A synthetic fragment of GHRH that prompts the pituitary to release growth hormone, marketed for anti-aging, body composition, and sleep. It reliably raises GH, but the anti-aging benefits rest on weak human evidence; the strongest data is in pediatric growth. Injection-site reactions hit roughly 1 in 6, hypothyroidism and fluid retention can occur, and long-term anti-aging safety is unstudied. Supplied through compounding pharmacies and banned by WADA.

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.

Overview

Sermorelin is a synthetic 29-amino-acid peptide that is the shortest fully functional fragment of GHRH (growth hormone-releasing hormone) — the natural signal your brain sends to trigger growth hormone production. It was previously FDA-approved as Geref for diagnosis in 1990 and pediatric treatment in 1997; it was discontinued in 2008, with approvals withdrawn in 2009. It works with your body's own feedback system rather than replacing growth hormone directly: it stimulates pituitary GH release through feedback-regulated pathways, but that mechanism does not establish protection from overdose.

How it works in the body

A synthetic version of the first 29 amino acids of GHRH (growth hormone-releasing hormone). It binds to GHRH receptors on pituitary somatotroph cells, stimulating natural growth hormone production and release in the body's normal pulsatile pattern, preserving the hypothalamic-pituitary feedback loop.

Research overview

Sermorelin works by binding to GHRH receptors on the pituitary gland, stimulating the natural pulsatile release of growth hormone — the same on-off pattern your body uses during deep sleep and after exercise. Unlike injecting growth hormone directly, sermorelin preserves the body's normal feedback loop. One six-month adult sermorelin trial doubled mean 24-hour GH and raised IGF-1 (the downstream marker of growth hormone activity) by about 34%. It has been the subject of 328 PubMed publications. Its proposed advantage over synthetic growth hormone (somatropin) is that it works through that feedback loop, though the feedback does not establish protection from overdose. Geref had diagnostic and pediatric treatment approvals. Marketing stopped in 2008; FDA withdrew both approvals effective June 18, 2009, and later found no safety or effectiveness reason for withdrawal.

Who researches Sermorelin?

Commonly researched by

  • People researching cognitive enhancement

    Studied for neuroprotective effects, memory, or cognitive performance.

  • People exploring sleep quality improvement

    Researched for effects on sleep architecture, circadian rhythm, or sleep quality.

Important considerations for

  • Those with Active cancer

    High

    GH stimulation via GHRH pathway may promote tumor growth.

  • Those with Pituitary damage

    High

    Requires functional pituitary to produce GH. Ineffective with pituitary damage.

  • Those with Diabetic retinopathy

    High

    GH/IGF-1 elevation can worsen proliferative retinopathy.

Safety & interactions

Do not use if

  • Active cancer

    High

    GH stimulation via GHRH pathway may promote tumor growth.

  • Pituitary damage

    High

    Requires functional pituitary to produce GH. Ineffective with pituitary damage.

  • Diabetic retinopathy

    High

    GH/IGF-1 elevation can worsen proliferative retinopathy.

How to read the ratings

Benefits
= confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Risks
= level of concern: High · Moderate · Low · Theoretical
Interactions
= direction with this peptide: Protective / Synergistic · Caution · Neutral

Risk summary(5)

Rated by level of concern

  • Injection site reactions (~1 in 6 patients)

    High

    Geref (sermorelin acetate) FDA label / RxList

  • Hypothyroidism observed in 6.5% of clinical study patients

    Moderate

    Geref (sermorelin acetate) FDA label / RxList

  • Potential GH-related effects: water retention, joint pain

    Moderate

    PMID 22869065; GH pharmacology

  • Large-scale long-term safety data for off-label anti-aging use lacking

    High

    Endotext, Growth Hormone and Aging (NBK279163); general literature

  • WADA banned for competitive athletes

    High

    WADA Prohibited List, S2 (Peptide Hormones, Growth Factors)

Interaction summary(6)

Rated by direction with this peptide

  • Glucocorticoids (corticosteroids)

    CautionModerate

    Concomitant glucocorticoid therapy may inhibit or blunt the GH response to sermorelin, reducing efficacy — the only drug interaction explicitly stated on the Geref label.

    Geref (sermorelin acetate) FDA label

  • Thyroid hormone status / levothyroxine (untreated hypothyroidism)

    CautionModerate

    Untreated hypothyroidism impairs the GH response to sermorelin, so thyroid function should be assessed and corrected before and during therapy to preserve efficacy.

    Geref (sermorelin acetate) FDA label

  • Somatostatin analogues (octreotide, lanreotide)

    CautionModerate

    Somatostatin is the physiologic antagonist of GHRH and directly suppresses somatotroph GH release, so it would blunt sermorelin-stimulated GH secretion.

    Endocrine physiology; Geref pharmacology

  • Cholinergic agents (e.g., pyridostigmine)

    SynergisticTheoretical

    Cholinergic agonists lower hypothalamic somatostatin tone and potentiate GHRH-stimulated GH release (the basis of pyridostigmine+GHRH GH-stimulation testing); anticholinergics conversely blunt it.

    GH-stimulation test literature

  • Exogenous growth hormone (somatropin)

    CautionLow

    Using exogenous GH with sermorelin adds redundant GH/IGF-1 effects; exogenous GH also suppresses endogenous somatotroph output via negative feedback, undercutting sermorelin's mechanism.

    Mechanism / GH physiology

  • Insulin / antidiabetic agents

    CautionTheoretical

    GH elevation can reduce insulin sensitivity and raise glucose, theoretically opposing glycemic control (fasting insulin rose in a GHRH-analog trial), though physiologic-dose sermorelin showed minimal glucose change in pediatric trials.

    PMID 22869065; PMID 8772599

Known risks(5)

  • Injection site reactions (~1 in 6 patients)

  • Hypothyroidism observed in 6.5% of clinical study patients — thyroid monitoring recommended

  • Potential GH-related effects: water retention, joint pain

  • Large-scale long-term safety data for off-label anti-aging use lacking

  • WADA banned for competitive athletes

Drug interactions(4)

  • Ipamorelin

    GHRH + GHS-R pathways complement each other. Similar concept to CJC-1295 + ipamorelin combo.

  • GHRP-2/GHRP-6

    GHRH + GHRP combination amplifies GH release

  • Exogenous HGH

    Both elevate GH. Exogenous GH would override sermorelin benefits and bypass feedback.

  • Glucocorticoids

    Suppress GH secretion, may blunt sermorelin response

Research & benefits

Evidence base

Evidence Level
Limited Clinical
Total Studies
328
Human Studies
45

Strongest evidence concerns pediatric GH deficiency. Adult evidence is limited and molecule-specific: a sermorelin cognition trial had 89 completers, while the 152-person cognition trial used tesamorelin. Studies of modified GHRH analogues should be identified separately.

Researched for(7)

Rated by confidence in the evidence

  • Natural GH stimulation

    High

    Human trials show pulsatile GH release; one adult sermorelin trial doubled mean 24-hour GH and raised IGF-1 by about 34%.

    Geref (sermorelin acetate) FDA label; PMID 8772599; PMID 16399214

  • Body composition

    Low

    Fat loss and lean gains seen mainly with a related molecule, not sermorelin directly.

    PMID 22869065 (tesamorelin RCT, different molecule); GH physiology

  • Cognitive function

    Medium

    Human trials report better executive function and overall cognition in older adults.

    PMID 16399214 (Vitiello 2006); PMID 22869065 (tesamorelin, different molecule)

  • Sleep quality

    Low

    Small studies suggest more slow-wave sleep in the elderly, though findings are mixed.

    PMID 8476038; contradicted by Antonijevic/Steiger (GHRH impairs sleep in women)

  • Pediatric growth

    Medium

    In GH-deficient children, height velocity nearly doubled from 4.1 to 8.0 cm per year.

    PMID 8772599 (Geref International Study Group)

  • Safety via self-regulation

    Speculative

    Mechanism-based reasoning suggests somatostatin feedback should limit overshoot, unlike direct GH.

    Geref label; PMID 8772599

  • Metabolic benefits

    Speculative

    Possible metabolic effects are preliminary and based on a related molecule, not sermorelin.

    PMID 22869065

Benefits(7)

  • Natural GH stimulation

  • Body composition

  • Cognitive function

  • Sleep quality

  • Pediatric growth

  • Safety via self-regulation

  • Metabolic benefits

Key studies(5)

  1. Thorner M et al.

    J Clin Endocrinol Metab

    1996

    Height velocity nearly doubled (4.1→8.0 cm/yr). 75% responded favorably.

  2. Khorram O et al.

    J Clin Endocrinol Metab

    1997

    5-month RCT using [Nle27]GHRH-(1–29)-NH2, a modified analogue rather than unmodified sermorelin: sustained GH elevation, increased IGF-I, and improved lean mass and insulin sensitivity in men.

  3. Baker LD et al.

    Arch Neurol

    2012

    This study used tesamorelin, not sermorelin. RCT n=152: improved executive function (p=.005) and verbal memory trend (p=.08).

  4. Friedman SD et al.

    JAMA Neurol

    2013

    This study used tesamorelin, not sermorelin. Used MRSI to show GABA increase in frontal brain regions.

  5. Sinha DK et al.

    Transl Androl Urol

    2020

    Sermorelin increases GH/IGF-1 with favorable body comp changes. Favorable safety.

What research suggests over time

  • Weeks 2-4

    FDA-era pediatric/adult trials

    Restored physiologic GH pulses; deeper sleep reported in adults with age-related GH decline.

  • Months 2-3

    Clinical use data

    IGF-1 climbing into youthful range; improved exercise tolerance and recovery.

  • Long-term

    Phase 2/3 trials

    Lean mass increase, fat reduction, and improved bone density in geriatric studies of GHRH analogs.

Regulation & availability

Why researchers look at it

A six-month randomized sermorelin trial reported cognitive benefits in 89 completers, doubled mean 24-hour GH and raised IGF-1 by about 34%. Preserves the body's natural pulsatile GH release pattern, with feedback that may limit GH release but does not establish protection from overdose. Its history of diagnostic and pediatric treatment approvals (withdrawn in 2009 for reasons other than safety or effectiveness) provides a regulatory track record most peptides lack.

Estimated cost
$150-350/mo compounding
FDA status
Previously FDA-approved 1997 (Geref, NDA 20-443). Manufacturer discontinued 2008 (commercial reasons). FDA withdrew NDA June 2009. FDA Federal Register 2013: confirmed NOT withdrawn for safety/efficacy. 503B outsourcing facilities may compound sermorelin acetate under FDA's interim Category 1 policy.
WADA status
Banned — GH secretagogue under prohibited substances (WADA/USADA)
Prescribability
Previously FDA-approved (Geref 1997, discontinued 2008 for commercial reasons). NOT on Category 2 list; 503B outsourcing facilities may compound sermorelin acetate under FDA's interim Category 1 policy. Available via compounding Rx.
Availability
503B outsourcing facilities may compound sermorelin acetate under FDA's interim Category 1 policy. NOT on Category 2 list. In 2013 FDA confirmed the withdrawal was not for safety/efficacy reasons. WADA banned.

International status

  • EU

    Not approved

  • US

    Previously FDA-approved (Geref, discontinued); sermorelin acetate is in 503B Category 1

  • Canada

    Available via compounding pharmacies

Regulatory timeline(4)

  1. 1997
    FDA approvalGeref approved for pediatric GH deficiency (NDA 20-443)
  2. 2008
    Manufacturer discontinuationEMD Serono discontinued for commercial reasons (not safety)
  3. 2009-06
    NDA withdrawnFDA withdrew approval after manufacturer discontinuation
  4. 2013-03
    FDA Federal Register noticeConfirmed withdrawal NOT for safety/efficacy reasons.

Sources & FAQs

Research sources(5)

Frequently asked questions(4)

How does it differ from HGH?

It stimulates your own GH production in natural pulsatile patterns and preserves somatostatin feedback, though that feedback does not establish protection from overdose.

Is it FDA-approved?

Was approved 1997 (Geref), discontinued 2008 for commercial reasons. FDA confirmed not for safety/efficacy. 503B outsourcing facilities may compound sermorelin acetate under FDA's interim Category 1 policy.

Time to results?

Sleep/energy 2-4 weeks. Body composition 8-12 weeks. Full benefits 6-12 months.

Side effects?

Injection site reactions (~1 in 6). Uncommon: flushing, headache, nausea. Hypothyroidism in 6.5% — monitor thyroid.